EHA 2026 | Cell Therapy Hub

Title	Author List	Presentation information
Axicabtagene Ciloleucel as Second-line Treatment in Patients with Late-relapsed LBCL: Interim Analysis of the LATE-R Clinical Trial from the Spanish Lymphoma Group GELTAMO	Mariana Bastos-Oreiro, Armando López Guillermo, Javier Delgado, Izaskun Zeberio, Eva Gonzalez-Barca, Hugo Luzardo, Anton…	Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF981
Axicabtagene Ciloleucel for the Treatment of R/R DLBCL in Brazil: The Impact of CAR T-cell Therapy Wait Time and Treatment Sequencing	João de Holanda Farias, Graeme Ball, Bradley Kievit, Rob Blissett, Jayr Schmidt	Abstract Code: PB3720
Biologic Correlates of Long‑Term Response After Brexucabtagene Autoleucel Therapy in MCL: Product Phenotype, PK, and Baseline Features	Sabina Adhikary, Kelly Speth, Colleen Schweitzer, Rhine Shen, Ioana Kloos, Marie José Kersten	Poster Session 2: Saturday, June 13 (18:45–19:45 CEST) Abstract Code: PS2201
CAR T Cell Therapy in Clinical Routine: Quantification of Real-World Hospital Resource Use Across CAR T Care Pathway in Germany	Katja Hesse, Isabell Kaufhold, Markus Finzsch, Florian Kron	Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF1415
Clinical and Economic Outcomes by Risk Group Among First-Line Patients with LBCL in the United States (US)-SEER-Medicare Data Analysis	Yi Lin, Liana Nikolaenko, Elyse Swallow, Madhu Palivela, Jinlin Song, Markqayne Ray, Sakshi Sethi, David Cobley, Matthew…	Abstract Code: PB3775
Cost-Effectiveness Analysis of Brexucabtagene Autoleucel in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Singapore	Esther Chan, Nurul A Abdul Halim, Tza Kai Diong, Emma New, Briana Tan, Francesca L.W.I. Lim	Poster Session 2: Saturday, June 13 (18:45–19:45 CEST) Abstract Code: PS2513
Cost-Effectiveness of Axicabtagene Ciloleucel for Treating Taiwanese Patients with R/R DLBCL and High-Grade B-cell Lymphoma After First-Line Treatment	Bor-Sheng Ko, Wen-Wen Yang, Yu-Chiao Wang, Diong Tza-Kai, Kuan-Der Lee, Raoh-Fang Pwu	Poster Session 2: Saturday, June 13 (18:45–19:45 CEST) Abstract Code: PS2514
Cost-Effectiveness of Axicabtagene Ciloleucel in Taiwanese Patients with R/R DLBCL and Primary Mediastinal B-Cell Lymphoma After Two Lines of Systemic Therapy	Kuan-Der Lee, Yu-Chiao Wang, Wen-Wen Yang, Diong Tza-Kai, Bor-Sheng Ko, Raoh-Fang Pwu	Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF1414
Exploring Global Variation in CAR T-Cell Therapy Practice Patterns for LBCL: Quantitative Research Findings	Samuel Yamshon, Gloria Ines Iacoboni Garcia-Calvo, David Qualls, Ajay Major, Lizamarie Bachier-Rodriguez, Anna Maria Sur…	Abstract Code: PB3712
Follow-Up Time–Adjusted Non-Relapse Mortality (NRM) in Patients With Non-Hodgkin Lymphoma Following CAR T-Cell Therapy Within Clinical Trials	Michael Leisch, Thomas Melchardt, Guido Ghilardi, Caroline Arber, Ulrich Jäger, Normann Steiner, Björn Chapuy, Robin San…	Poster Session 2: Saturday, June 13 (18:45–19:45 CEST) Abstract Code: PS2112
International Expert Consensus on Real-World CAR T-Cell Eligibility in LBCLs: An e-Delphi Study	Catherine Thieblemont, Isabelle Fleury, Mazyar Shadman, Tobias A.W. Holderried, Graham Collins	Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF1023
Real-World Treatment Patterns and Survival Outcomes in Patients With Newly Diagnosed High-Risk LBCL	Ran Reshef, Javier Munoz, Babatunde Adedokun, Qian Huang, Hil Hsu, Nan Liu, Madhu Palivela, Zhen-Huan Hu, Liana Nikolaen…	Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF1014

CAR, chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma; LBCL, large B-cell lymphoma; MCL, mantle cell lymphoma; (R/R) DLBCL, (relapse/refractory) diffuse large B-cell lymphoma.

FROM DATA TO DECISIONS:

IMPROVING PATIENT OUTCOMES FOR CAR T IN DLBCL

Friday, 12 June 2026 | 08:00–09:30 CEST

K1 Auditorium, Stockholmsmässan, Massvagen 1, 125 30 Alvsjö, Sweden

This promotional symposium is organised and funded by Gilead and Kite through Kite Pharma, Inc. Kite products will be mentioned, and prescribing information is available under resources below.

Agenda

08:00–08:05

Welcome and introduction

Co-Chair: Prof. Karin Ekström Smedby
Karolinska University Hospital, Stockholm, Sweden

08:05–9:15

Improving patient outcomes for CAR T in DLBCL

Building the foundation: Strategies to optimise patient outcomes

Dr Megan Melody
Tampa General Hospital Cancer Institute, Tampa, FL, USA

Evolving strategies: Acute and long-term adverse event management

Co-Chair: Dr Matthew Frank
Stanford University School of Medicine, Stanford, CA, USA

Navigating life after CAR T, Part I: Patient experience and long-term well-being

Emily John
University Hospital of Wales, Cardiff, Wales

Navigating life after CAR T, Part II: Patient experience and long-term well-being

Surabhi Chaturvedi
Kings College Hospital, London, UK

09:15–09:25

Audience Q&A

All, facilitated by Prof. Karin Ekström Smedby and Dr Matthew Frank

09:25–09:30

Conclusion and closing remarks

Prof. Karin Ekström Smedby

AE: adverse event; CAR T: chimeric antigen receptor T cell; DLBCL: diffuse large B-cell lymphoma.

DELIVERING OUTCOMES, NOT JUST CELLS:

WHY SPEED AND RELIABILITY MATTER FOR CAR T PATIENTS

Saturday, 13 June 2026 | 10:00–11:30 CEST

A2-3 Hall, Stockholmsmässan, Massvagen 1, 125 30 Alvsjö, Sweden

This non-promotional symposium is organised and funded by Gilead and Kite through Kite Pharma, Inc. The safety and efficacy of investigational agents have not been established, and they have not received marketing authorisation in this setting. There is no guarantee that investigational agents and/or uses will receive Health Authority approval and/or become commercially available.

Agenda

10:00–10:10